Navigation Links
OncoGenex Pharmaceuticals, Inc. Provides Update on Clinical Development Program and Reports Financial Results for Fourth Quarter and Year End 2012
Date:3/7/2013

in patients with disease progression following treatment with a first-line, platinum-based chemotherapy doublet regimen.  

OGX-427 Clinical Development Highlights

  • In December 2012, the Company announced the initiation of the Pacific trial, an investigator-sponsored, randomized Phase 2 study evaluating OGX-427 in approximately 80 men with CRPC who are experiencing a rising prostate-specific antigen (PSA) while receiving Zytiga® (abiraterone acetate). The study is currently enrolling at sites in the United States and Canada.
  • The company-sponsored, randomized Phase 2 clinical trial of OGX-427 in combination with gemcitabine and cisplatin in patients with metastatic bladder cancer, Borealis-1, continues to enroll patients throughout the United States, Canada and Europe. The study aims to enroll approximately 180 patients and is expected to complete patient accrual in the second half of 2013.
  • The Company also recently announced plans for the initiation of an investigator-sponsored, randomized Phase 2 study evaluating OGX-427 in patients with advanced or metastatic bladder cancer who have disease progression following initial platinum-based chemotherapy.  The trial, Borealis-2, will seek to enroll approximately 200 patients to receive either OGX-427 plus docetaxel treatment or docetaxel treatment alone and is expected to begin in the first half of 2013.
  • Pacific, Borealis-1 and Borealis-2 are part of the "ORCA" (On-going studies evaluating treatment Resistance in CAncer) program that encompasses clinical studies of OGX-427 across multiple cancer indications. Plans to initiate additional studies as part of the ORCA program will be announced in the coming months.
  • Financial Update and Results

  • Revenue for the fourth quarter and year ended December 31, 2012 increased to
    '/>"/>

  • SOURCE OncoGenex Pharmaceuticals, Inc.
    Copyright©2012 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7

    Related medicine technology :

    1. OncoGenex Pharmaceuticals, Inc. Reports Second Quarter and First-Half 2012 Financial Results and Reviews Clinical Development Highlights for Custirsen and OGX-427
    2. OncoGenex Announces Initiation of the Phase 3 "AFFINITY" Trial for Patients with Advanced Prostate Cancer
    3. OncoGenex Announces Plans for the Initiation of the Borealis-2 Clinical Trial Evaluating OGX-427 in Combination with Second-Line Therapy for Bladder Cancer
    4. Almost 50 Percent of the Glaucoma Patient Population Remains Untreated, Signifying a Vast Market for Glaucoma Pharmaceuticals, Finds Frost & Sullivan
    5. Provectus Pharmaceuticals, Inc.s Investor Presentation Now Available for On-demand Viewing at RetailInvestorConferences.com
    6. Keryx Biopharmaceuticals, Inc. To Host Conference Call on First Quarter 2012 Financial Results
    7. Keryx Biopharmaceuticals, Inc. Announces First Quarter 2012 Financial Results
    8. Auxilium Pharmaceuticals, Inc. to Present At The BofAML 2012 Health Care Conference
    9. Depomed Announces Receipt of $1 million Milestone Payment From Ironwood Pharmaceuticals, Inc.
    10. Auxilium Pharmaceuticals, Inc. and FCB I LLC Announce the Issuance of Composition of Matter Patent Covering Testim
    11. Auxilium Pharmaceuticals, Inc. Raises Revenue Guidance And Reduces Net Loss Guidance For 2012
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:7/11/2014)... 2014  Veran Medical Technologies, a U.S. ... positive, cost-effective final results for the initial ... SPiNPerc endobronchial percutaneous biopsy study results support ... biopsy when a traditional bronchoscopic method is ... positive financial outcomes when more can be ...
    (Date:7/10/2014)...  Major advances in radiation therapy and radiosurgery ... in a three-day Oncology Summit taking place in ...  Renowned national and international cancer experts from seven countries ... knowledge on modern technologies making treatment for cancer ... The Summit will address a wide spectrum ...
    (Date:7/10/2014)...  Breg, Inc., a premier provider of sports ... knee brace with new innovations to help people, ... to active lifestyles.  FreeRunner,s patent-pending design acts on ... when patients need it most, and the ability ... Patellofemoral issues are the most common cause of ...
    Breaking Medicine Technology:Veran Medical Publishes Lung Cancer Patient Management Study 2Improving quality and access to advanced cancer care in India and South Asia 2Improving quality and access to advanced cancer care in India and South Asia 3Improving quality and access to advanced cancer care in India and South Asia 4Improving quality and access to advanced cancer care in India and South Asia 5Breg Introduces Knee Brace to Help Runners with Patellofemoral Pain Syndrome 2
    ... YORK, Sept. 8, 2011 Reportlinker.com announces ... available in its catalogue: ... http://www.reportlinker.com/p0611073/Global-Intravascular-Ultrasound-IVUS-Industry.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Medical_I This ... Ultrasound (IVUS) in US$ Million by the ...
    ... Pa., Sept. 8, 2011 Auxilium Pharmaceuticals, Inc. ... company, today announced additional three year recurrence data ... Long-term Evaluation of Success Study (CORDLESS) for XIAFLEX ... of adult Dupuytren,s contracture patients with a palpable ...
    Cached Medicine Technology:Global Intravascular Ultrasound (IVUS) Industry 2Global Intravascular Ultrasound (IVUS) Industry 3Global Intravascular Ultrasound (IVUS) Industry 4Global Intravascular Ultrasound (IVUS) Industry 5Global Intravascular Ultrasound (IVUS) Industry 6Global Intravascular Ultrasound (IVUS) Industry 7Global Intravascular Ultrasound (IVUS) Industry 8Global Intravascular Ultrasound (IVUS) Industry 9Global Intravascular Ultrasound (IVUS) Industry 10Global Intravascular Ultrasound (IVUS) Industry 11Global Intravascular Ultrasound (IVUS) Industry 12Global Intravascular Ultrasound (IVUS) Industry 13Auxilium Pharmaceuticals Announces Additional Data from Three-Year XIAFLEX® Recurrence Study in Dupuytren's Contracture in E-poster at ASSH Meeting 2Auxilium Pharmaceuticals Announces Additional Data from Three-Year XIAFLEX® Recurrence Study in Dupuytren's Contracture in E-poster at ASSH Meeting 3Auxilium Pharmaceuticals Announces Additional Data from Three-Year XIAFLEX® Recurrence Study in Dupuytren's Contracture in E-poster at ASSH Meeting 4Auxilium Pharmaceuticals Announces Additional Data from Three-Year XIAFLEX® Recurrence Study in Dupuytren's Contracture in E-poster at ASSH Meeting 5Auxilium Pharmaceuticals Announces Additional Data from Three-Year XIAFLEX® Recurrence Study in Dupuytren's Contracture in E-poster at ASSH Meeting 6Auxilium Pharmaceuticals Announces Additional Data from Three-Year XIAFLEX® Recurrence Study in Dupuytren's Contracture in E-poster at ASSH Meeting 7Auxilium Pharmaceuticals Announces Additional Data from Three-Year XIAFLEX® Recurrence Study in Dupuytren's Contracture in E-poster at ASSH Meeting 8Auxilium Pharmaceuticals Announces Additional Data from Three-Year XIAFLEX® Recurrence Study in Dupuytren's Contracture in E-poster at ASSH Meeting 9
    (Date:7/13/2014)... Advanced boilers are preferred over ... of fossil fuels, produce high-capacity power, emit fewer ... global warming and climate change concerns, many countries ... gas emissions and pollutants coming from fossilfuel-based power ... global advance boilers market., The global power rental ...
    (Date:7/13/2014)... 13, 2014 According to a ... Computing Market by Component (processor, GPU, DSP, connectivity), ... Medical), and Geography - Forecast and Analysis to ... Processing & Computing Market is expected to reach ... of 20.75% from 2014 to 2020. , Browse ...
    (Date:7/13/2014)... A Massachusetts couple who have done ... associated with power morcellators ( http://www.gynecaremorcellatorlawsuit.com/ ) finally ... regulators, as they presented poignant testimony on the second ... (FDA) advisory panel meeting convened to address the issue, ... Democrat and Chronicle, Dr. Hooman Noorchashm and his wife, ...
    (Date:7/13/2014)... 2014 The Pearland, Texas location of The ... from four months to 12 years of age that offers ... birthday parties and Summer Camps, is now under new ownership. ... Pearland after spending over six years at The Little ... Director. , Berry has over ten years of experience ...
    (Date:7/13/2014)... York, New York (PRWEB) July 13, 2014 ... lawsuits ( http://www.transvaginalmeshlawsuithelp.com/ ) filed against Johnson ... litigation’s second bellwether trial, which is expected to get ... Order issued in the U.S. District Court, Southern District ... Conference will be held on August 7, 2014 at ...
    Breaking Medicine News(10 mins):Health News:North America Advanced Boilers Market is Expected to Reach $518.7billion by 2019 - New Report by MicroMarket Monitor 2Health News:North America Advanced Boilers Market is Expected to Reach $518.7billion by 2019 - New Report by MicroMarket Monitor 3Health News:Heterogeneous Mobile Processing & Computing Market Worth $61.70 Billion by 2020 – New Report by MarketsandMarkets 2Health News:Heterogeneous Mobile Processing & Computing Market Worth $61.70 Billion by 2020 – New Report by MarketsandMarkets 3Health News:Heterogeneous Mobile Processing & Computing Market Worth $61.70 Billion by 2020 – New Report by MarketsandMarkets 4Health News:Couple Who Brought Attention to Morcellator Cancer Risks Testify on Second Day of FDA Advisory Panel Meeting, Bernstein Liebhard LLP Reports 2Health News:Couple Who Brought Attention to Morcellator Cancer Risks Testify on Second Day of FDA Advisory Panel Meeting, Bernstein Liebhard LLP Reports 3Health News:Couple Who Brought Attention to Morcellator Cancer Risks Testify on Second Day of FDA Advisory Panel Meeting, Bernstein Liebhard LLP Reports 4Health News:The Little Gym of Pearland, TX Now Under New Ownership and Management 2Health News:Ethicon Vaginal Mesh Lawsuits Move Forward, As Federal Court Schedules Pretrial Conference for Second Bellwether Case, Bernstein Liebhard LLP Reports 2Health News:Ethicon Vaginal Mesh Lawsuits Move Forward, As Federal Court Schedules Pretrial Conference for Second Bellwether Case, Bernstein Liebhard LLP Reports 3Health News:Ethicon Vaginal Mesh Lawsuits Move Forward, As Federal Court Schedules Pretrial Conference for Second Bellwether Case, Bernstein Liebhard LLP Reports 4
    ... WASHINGTON, Sept. 25 The following was,released today by ... tonight, the House of Representatives is expected to vote ... for,illegal immigrants and uses budgetary gimmicks to capture new ... private insurance and,onto government-run health care. Here,s just a ...
    ... Gentiva Health,Services, Inc. (Nasdaq: GTIV ), the ... services, today announced that it has,filed a universal ... (SEC) for the periodic offering and sale of ... common stock and warrants,after the SEC declares the ...
    ... CHARLOTTESVILLE, VA (September 25, 2007) Birds, fish and ... generally cannot: re-grow damaged or lost inner ear hair ... deficiencies and disabling balance problems in an estimated 250 ... treatments, research and development efforts have been hindered by ...
    ... Under Medicare Creates Two-Tiered System of Cancer Care ... Face Avoidable Blood Transfusions, HOUSTON, Sept. 25 ... over 1,100 oncologists across the,country, today expressed "deep ... for Medicare and Medicaid Services (CMS) -- the ...
    ... American Society of,Transplantation (AST) Past President Jeffrey ... Representatives, Information, Policy, Census and,National Archives Subcommittee of ... subcommittee to use public policy and,technology to strengthen ... Dr. Crippin, over 97,000 individuals are awaiting a,life-saving ...
    ... Sept. 25 The HealthCentral Network,Inc. ... an author,and psychotherapist who has asthma and ... expert. Miller, dubbed,"Allergic Girl", first gained online ... Nuts", which catalogues her daily challenges with ...
    Cached Medicine News:Health News:'Compromise' SCHIP Deal Substitutes Ideology for Common Sense 2Health News:Gentiva(R) Health Services Files Universal Shelf Registration Statement 2Health News:Gentiva(R) Health Services Files Universal Shelf Registration Statement 3Health News:Study expected to boost research for hearing and balance therapies 2Health News:Cancer Doctors Across America 'Stunned' at Government's Ruling Restricting Anemia Management Protocols for Cancer Patients, Call Ruling 'Interference' in Practice of Medicine 2Health News:Cancer Doctors Across America 'Stunned' at Government's Ruling Restricting Anemia Management Protocols for Cancer Patients, Call Ruling 'Interference' in Practice of Medicine 3Health News:American Society of Transplantation's Past President Testifies Before Congress at Forum on Organ Donation 2Health News:Leading Asthma and Allergy Author and Counselor Joins The HealthCentral Network As Expert 2Health News:Leading Asthma and Allergy Author and Counselor Joins The HealthCentral Network As Expert 3
    CRP Liquid Conrtols level 3...
    Therapeutic Drug Calibrator Series...
    The IRN method used on the Dimension clinical chemistry system is an in vitro diagnostic test intended for the quantitative determination of iron in serum....
    The AST method used on the Dimension clinical chemistry system is an in vitro diagnostic test intended for the quantitative determination of aspartate aminotransferase activity in serum or plasma...
    Medicine Products: